Cambridge-based biotech company BiologIC Technologies is driving the development and manufacture of cost-effective drugs and vaccines. It does this by using 3D-printed ‘lab-on-a-chip’ platforms that integrate multiple laboratory functions on a single piece.
BiologIC’s miniature devices enable faster, more efficient and cost-effective analysis of biological samples. Their applications range from drug testing to point-of-care diagnostics. Through the Analysis for Innovators (A4I) grant funding program operated by Innovate UK, the company was able to access the expertise and advanced equipment of the National Measurement Laboratory (NML).
BiologIC says it is now able to demonstrate improved biocompatibility and stability of its “lab-on-a-chip.” This means that pharmaceutical manufacturers and CDMOs (Contract, Design and Manufacturing Organizations) can now accelerate the work required to develop a minimally usable product, which will ultimately lead to faster time to market and more affordable drugs and vaccines.
Dr. Colin Barker, Chief Scientific Officer at BiologIC Technologies, emphasized the importance of the collaboration, “Without access to the NML’s state-of-the-art analyses and, more importantly, world-class expertise made possible by A4I funding, it likely would have taken us several years to gain the same insights.”
“Our customers seek to produce advanced neologism products with robust reproducibility at large scale. The greater understanding of our materials provided by the A4I grant will allow us to standardize and streamline our production methods, leading to reproducible results at lower cost,” added Dr. Barker.
Subscribe to our Newsletter
3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
